New York University Grossman School of Medicine, 550 First Avenue, New York, NY, 10016, USA.
New York University Langone Fertility Center, 660 First Avenue, 5th Floor, New York, NY, 10016, USA.
J Assist Reprod Genet. 2022 Aug;39(8):1789-1796. doi: 10.1007/s10815-022-02534-9. Epub 2022 Jun 18.
To assess assisted reproductive technology (ART) outcomes in patients with one ovary compared to two ovaries.
We performed a retrospective cohort study of all patients with one ovary who underwent ≥ 1 ART cycle between 2012 and 2020 at a large university-affiliated fertility center. Patients were 3-to-1 matched with two ovary controls during the same period. Primary outcome was metaphase II oocytes (MIIs) retrieved per cycle. Secondary outcomes included ovarian reserve markers, laboratory outcomes, and live birth rates (LBRs).
A total of 104 one ovary patients (158 cycles; median age 35.5 years) were matched to 312 two ovary patients (474 cycles; median age 35.0 years). In one ovary patients, anti-Mullerian hormone was lower (median 1.1 vs. 2.2, p < 0.01) and day 2 follicle-stimulating hormone was higher (median 7.4 vs. 6.2, p < 0.01). One ovary patients yielded median 7.5 MIIs and 10 oocytes per cycle, fewer than two ovary patients (11.0 and 14.5, respectively; p < 0.01). However, one ovary patients had ≥ 50% the MII and oocyte yield of two ovary patients (Z > 5.8, p < 0.01). Fertilization and blastocyst formation rates, euploidy rate, and rate of ≥ 1 embryo for transfer were equivalent between groups (p > 0.40). Among the one and two ovary groups, LBRs per transfer (45.8% vs. 46.6%, p = 1.00) and per patient who underwent transfer (68.3% vs. 73.9%, p = 0.55) were equivalent.
One ovary patients yielded fewer MIIs and oocytes than two ovary patients, but had ≥ 50% the yield of two ovary patients, suggesting a compensatory mechanism in oocyte yield in the solitary ovary. One and two ovary patients had equivalent LBRs.
评估单侧卵巢与双侧卵巢患者接受辅助生殖技术（ART）的结局。
我们对 2012 年至 2020 年期间在一家大型大学附属生育中心接受至少 1 次 ART 周期的单侧卵巢患者进行了回顾性队列研究。同期对单侧卵巢患者进行了 3：1 双侧卵巢对照匹配。主要结局为每周期获得的中期 II 卵母细胞（MII）数。次要结局包括卵巢储备标志物、实验室结局和活产率（LBR）。
共有 104 例单侧卵巢患者（158 个周期；中位年龄 35.5 岁）与 312 例双侧卵巢患者（474 个周期；中位年龄 35.0 岁）进行了匹配。单侧卵巢患者的抗苗勒管激素水平较低（中位数 1.1 vs. 2.2，p<0.01），且基础卵泡刺激素水平较高（中位数 7.4 vs. 6.2，p<0.01）。单侧卵巢患者每周期获得的 MII 数和卵母细胞数中位数分别为 7.5 个和 10 个，少于双侧卵巢患者（分别为 11.0 个和 14.5 个；p<0.01）。然而，单侧卵巢患者有≥50%的 MII 和卵母细胞产量与双侧卵巢患者相当（Z 值>5.8，p<0.01）。两组间受精率和囊胚形成率、整倍体率和用于移植的≥1 个胚胎率相当（p>0.40）。在单侧和双侧卵巢组中，每移植周期的活产率（45.8% vs. 46.6%，p=1.00）和每接受移植患者的活产率（68.3% vs. 73.9%，p=0.55）相当。
单侧卵巢患者的 MII 数和卵母细胞数少于双侧卵巢患者，但有≥50%的双侧卵巢患者的产量，这表明单侧卵巢中存在卵母细胞产量的补偿机制。单侧和双侧卵巢患者的活产率相当。
